Abstract
Clinical trial practitioners need to enhance their technical skills and knowledge about DCTs, enhance the overall level of the industry, and promote the better implementation and application of DCTs in China.
Introduction
As the global clinical research landscape shifts toward digital transformation, Decentralized Clinical Trials (DCTs) have emerged as a vital alternative to traditional, site-centered models. By leveraging tools such as telemedicine, wearable sensors, and remote monitoring, DCTs aim to reduce participant burden and improve recruitment rates. This study, published in Frontiers in Medicine, examines the readiness of the Chinese clinical research industry to adopt these methods, focusing on the knowledge, attitudes, and practical experiences of front-line practitioners.
The Knowledge Gap Among Practitioners
While the concept of decentralization is gaining traction, there is a notable disparity in knowledge levels across different professional roles. The study surveyed 621 practitioners, including Clinical Research Associates (CRAs), Coordinators (CRCs), and Program Managers (PMs).
Analysis revealed that Program Managers generally possess a deeper understanding of DCT concepts and regulations compared to their counterparts. While 77.5% of all respondents understood basic DCT concepts, only 58.1% felt familiar with the relevant domestic and international regulations. This discrepancy suggests that while the industry is aware of the trend, the regulatory framework remains a point of uncertainty for many.
Current Practices: The "Willingness-Experience" Gap
One of the most striking findings of the research is the gap between practitioner enthusiasm and actual implementation. Nearly 80% of respondents expressed a willingness to participate in DCTs, yet practical experience remains "shallow."
Currently, DCT activities in China are heavily weighted toward the early stages of the trial lifecycle. Internet recruitment is the most common activity, utilized by 27.4% of respondents. In contrast, more technically demanding elements like remote monitoring and auditing (7.4%) or home nurse assistance (9.7%) see much lower adoption. This indicates that while finding patients digitally has become standard, managing trial data and patient safety remotely remains a significant hurdle.
Barriers to Implementation
Practitioners identified technical and data-related issues as the primary obstacles to DCT adoption, rather than financial concerns. Specifically, "technical barriers and compatibility issues" (54.1%) and the "reliability and accuracy of data" (53.8%) were cited as the top concerns.
Interestingly, the type of enterprise played a role in practitioner attitudes. Those working at domestic pharmaceutical companies showed higher willingness to adopt DCTs, likely driven by the need to remain competitive and shorten R&D cycles in a rapidly evolving market.
Conclusion and Future Directions
For DCTs to become a mainstay in China, the study suggests a multi-pronged approach. First, there is a clear need for standardized, detailed guidance regarding remote data compliance and technical integration. Second, the industry should move toward "hybrid" models that incrementally introduce decentralized elements into traditional workflows. Finally, a tiered training system is essential to bridge the technical skills gap among CRCs and CRAs, ensuring that the front-line workforce is equipped to handle the complexities of digital clinical research. By addressing these technical and regulatory hurdles, China can better promote the implementation and application of DCTs to improve the overall efficiency of the clinical trial industry.
Summary updated